GET DAILY SIGNALSCellectis (CLLS) Shares Decline -29% Over 30 Days Following Major Pivot
Key Takeaways
- Cellectis (CLLS) shares fell roughly 29% over the last 30 days, extending a much larger multi-month decline.
- The drop followed a strategic pivot away from its lead blood-cancer CAR-T programs (lasme-cel and eti-cel) toward in vivo gene editing for cardiovascular disease.
- Citizens JMP downgraded the stock to Market Perform, while Barclays moved to Sell with a $1.30 price target, though other analysts kept Buy ratings.
- Management said the restructuring extends the company's cash runway into the second half of 2028.
- Key clinical catalysts, including Phase 1 data for HEAL-101 and HEAL-201, are now pushed out to late 2027 and 2028.
- For more detail on valuation, results, and expectations, explore Cellectis Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, visit Trending AI Robots.
Cellectis (CLLS) Company Overview and Market Position
Cellectis S.A. is a clinical-stage biotechnology company headquartered in Paris, France, focused on gene-editing technologies. The company pioneered TALEN gene-editing and has built a portfolio around allogeneic, or "off-the-shelf," chimeric antigen receptor T-cell (CAR-T) therapies, which use immune cells from healthy donors rather than a patient's own cells. Investors have historically followed CLLS for its potential to broaden access to cell therapy and for its partnerships with larger pharmaceutical and biotech companies, including AZN, ALLO, Servier, and IOVA. As a clinical-stage company with limited revenue, CLLS's valuation is tied primarily to pipeline milestones and its ability to fund development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Cellectis (CLLS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Cellectis shares fell from a closing price near $1.48 to roughly $1.05, a decline of about 29%. The move was driven by a steep sell-off that began in mid-September, when the company announced a major strategic shift, and continued through October as the stock set fresh multi-month lows.
The broader quarterly picture is even weaker. Roughly three months ago the stock traded above $2.70, meaning shares have lost more than 60% of their value over that span. The bulk of the damage was concentrated in a single session in mid-September, when the stock fell more than 40%, followed by a further gradual decline into late October.
What Drove CLLS Stock Price in the Last 30 Days
The primary catalyst was Cellectis's announcement that it is discontinuing development of lasme-cel and eti-cel, its two lead allogeneic CAR-T candidates for blood cancers. The company cited improvements in existing cancer treatments and rising competition from bispecific antibodies and newer in vivo CAR-T approaches as reasons the market had become less attractive. Instead, Cellectis is pivoting to in vivo gene editing targeting cardiovascular risk factors, led by HEAL-101 (for very high triglycerides) and HEAL-201 (for elevated lipoprotein cholesterol).
The pivot triggered a wave of analyst reactions. Citizens JMP downgraded the stock to Market Perform from Outperform, noting that the change pushes major clinical catalysts out to late 2027 and 2028. Barclays downgraded Cellectis to Sell with a $1.30 price target, while Robert W. Baird maintained a Buy rating and Wells Fargo reiterated a Hold. The net effect was a sharp repricing as investors digested a longer timeline to clinical data and revenue. From what I see, this shift has clearly altered near-term expectations for the stock.
What Drove CLLS Stock Performance Over the Last Quarter
Over the last quarter, Cellectis shares were pressured by a combination of strategic uncertainty and a shrinking near-term catalyst pipeline. Before the pivot, the stock had been trading in a range as investors weighed early-stage cell-therapy data against a limited commercial runway. The decision to abandon the two most advanced cancer programs removed the nearest milestones from the calendar and refocused the company on earlier-stage cardiovascular assets, which are several years away from meaningful readouts. The resulting downgrades and a decline in institutional positioning compounded the selling pressure, leaving the stock near multi-year lows despite roughly $169 million in reported cash reserves.
CLLS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on Cellectis's execution of its new cardiovascular strategy. Near-term attention centers on continued updates to the HEAL-101 and HEAL-201 programs, with early Phase 1 data expected in the second half of 2027 and the first half of 2028, respectively. Quarterly results and cash-burn guidance will also be closely watched, given that the restructuring is intended to extend the runway into the second half of 2028. Broader factors such as competitive developments in in vivo gene editing, regulatory timelines, and the status of the company's existing partnerships with AZN, ALLO, Servier, and IOVA may also influence sentiment. As with all clinical-stage biotechnology companies, the outcome of ongoing trials and financing conditions remain key variables. I’m watching this closely as the timeline for data readouts stretches further out.
Using Tickeron AI Trading Bots for Research
In my own work, I frequently review Tickeron’s AI Trading Bots to compare automated strategies across volatile sectors like biotech. The platform offers a range of bots with different timeframes and performance metrics, which helps put individual stock moves like the recent CLLS decline into broader context without replacing traditional fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLLS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 12, 2026
CLLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where CLLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CLLS just turned positive on October 05, 2026. Looking at past instances where CLLS's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +1.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLLS advanced for three days, in 170 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLLS as a result. In 81 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CLLS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.575) is normal, around the industry mean (3.037). P/E Ratio (-1.641) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (2.441) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. CLLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are the Contribution Deadlines for My Self-Employed 401(k)?
What Is the Real Estate Price Reality?
What is the Deutschmark? and What Were the Key Factors Behind the Deutschmark's Strength and Stability?
What Is Stagflation, and How Does It Impact Economies?
Week (January 13 - 17) in Review: Financial Leaders
General Information
a genome engineering company of pre-engineered products for pharmaceutical industry, cell therapies, seed companies, and laboratory researchers
Industry Biotechnology
Advertisement